P. Zachée MD, PhD

P3.13 Plerixafor in autologous haematopoietic stem cell mobilization in Belgium

Treatment of mantle cell lymphomas: recommendations of the Belgian Hematological Society

Summary

Mantle cell lymphoma was recognised in the nineties and is characterised by the t(11;14)(q13;q32) translocation which results in overexpression of cyclin D1.¹ This disease represents approximately 6% of all non-Hodgkin’s lymphomas. Mantle cell lymphoma generally affects patients over 60 years-old. Most patients have advanced disease (>70 % Ann Arbor stage IV). Several efforts have been made to predict outcome in mantle cell lymphoma. The cell-proliferation marker Ki-67, the Mantle Cell Lymphoma International Prognostic Index, fluorodeoxyglucose positron emission tomography and minimal residual disease are prognostic tools. For young patients, chemoimmunotherapy followed by high-dose chemotherapy plus stem cell transplantation is the treatment of choice. For the main group of older patients, chemo-immunotherapy followed by maintenance with rituximab is the gold standard. In relapses, temsirolimus is actually registered and new drugs, such as ibrutinib, are currently evaluated with promising preliminary results.^2–5

(BELG J HEMATOL 2014;5(3):89–96)

O.3 Comparison of 2 nonmyeloablative regimens for allogeneic HCT: a phase II randomized study from the HCT committee of the BHS

P2.06 Diagnosis of lymphoma in a patient under treatment with azacytidine

Treatment of peripheral T-cell lymphomas: recommendations of the Belgian Hematological Society (BHS)

Summary

The sub-committee on lymphoproliferative disorders of the Belgian Hematological Society has met several times to prepare guidelines on the management of patients with peripheral T-cell lymphomas. Each panellist’s expert provided interpretation of the evidence, based on literature review and personal experience. The available evidence was systematically discussed prior to formulating recommendations. A systematic approach to obtain consensus of expert opinion was used. After each meeting, the draft guideline was circulated to all experts for comment and approval. The present guidelines focus on general management of peripheral T-cell lymphomas with special emphasis on more specific disease-adapted strategies.

(BELG J HEMATOL 2013;4(3):90–101)

A rare cause of lymphadenopathy in a young woman: the Kikuchi-Fujimoto disease

Summary

A 16-year-old Moroccan woman was referred to our centre because of bilateral cervical lymphadenopathy, high fever and weight loss. A malignant lymphoma was suspected in the lymph node biopsy. Histopathologic review of the lymph node biopsy showed extensive necrosis and nuclear debris with no viable remaining cells. A new lymph node biopsy was performed and the diagnosis of histiocytic necrotising lymphadenitis (Kikuchi-Fujimoto disease) was made. This is a rare, benign and self-limiting disease that mainly affects young women.

BELG J HEMATOL 2013;4(2):66–69)

P.07 Interim analysis of the randomized EORTC/ LYSA/FIL Intergroup H10 trial on early PET-scan driven treatment adaptation in stage I/II Hodgkin lymphoma